Status:
RECRUITING
A Prospective Cohort Study on Primary Cutaneous Amyloidosis
Lead Sponsor:
Army Medical University, China
Conditions:
Primary Cutaneous Amyloidosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this clinical trial is to find out whether the combination of tocilizumab tablets and acitretin capsules is more effective than acitretin capsules alone in treating primary cutaneous amyloi...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old, without infectious diseases such as "hepatitis B" and "tuberculosis" and major underlying diseases (gender not limited);
- "Outpatient Diagnosis" includes "primary cutaneous amyloidosis", "macular amyloidosis" or "lichen amyloidosis";
- Visited the outpatient department for PCA treatment for 4 times or more;
- The medication record shows "Avastin Capsules" and/or "Tofacitinib Citrate";
- The medical record fully records baseline characteristics, medication dosage, efficacy assessment and adverse events.
Exclusion
- Nodular amyloidosis or combined with other types of amyloidosis (such as systemic amyloidosis);
- During the study period, other immunosuppressants (such as glucocorticoids, methotrexate) or biologics were used;
- Incomplete medical records such as demographic data, laboratory parameters, prescription administration and patient prognosis, as well as irregular treatment, etc.
Key Trial Info
Start Date :
March 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06998875
Start Date
March 1 2025
End Date
December 1 2025
Last Update
August 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University)
Chongqing, Chongqing Municipality, China, 400038